Human Vaccines & Immunotherapeutics · 2018 · 16 citations · 17 references
Veterinary MedicineImmunologyPediatricsImmunizationVaccine ImmunologyVaccinologyClinical Vaccine TrialsVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyVaccine Safety SurveillanceAdverse Vaccine ReactionsComparative Vaccine SafetyControl Group DesignMatched Control GroupOverall Vaccine EffectivenessPhase Iii Clinical TrialsPolysaccharide VaccinesSerious Adverse Events
To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years. We conducted a randomized, double-blinded, active controlled trial, in which 1760 participants were randomly assigned in a 1:1 ratio to receive one dose of either the test vaccine or the control commercial vaccine. The surveillance period was 28 days. The 2-fold increase rate of anti-pneumococcal for 23 serotypes varied from 49.71% to 90.96% in the treatment group and from 44.52% to 88.24% in the control group. According to -10% non-inferiority margin and 95% confidence intervals of rate difference, all the 23 serotypes of the treatment group were non-inferiority to the control group. The 2-fold increase rate of anti-pneumococcal antibody were significantly higher in the treatment group for 11 serotypes including 1, 2, 3, 4, 10A, 11A, 14, 18C, 20, 22F, and 23F. Serious adverse events occurred in 2 in 879 (0.23%) participants in the treatment group and 2 in 880 (0.23%) participants in the control group, and all the adverse events were unrelated to the vaccination. The overall adverse reaction frequency showed no difference between the treatment (51.19%) and control group (47.95%), and most adverse reactions were mild or moderate in intensity. The newly PPV23 is immunologically non-inferior to the control commercial vaccine and well tolerated in healthy Chinese population aged ≥ 2 years. Trial registration: ClinicalTrial.gov identifier: NCT02451969.
17
Katherine A. Robinson · JAMA · 2001 · 657 citations
J. Pekka Nuorti, Cynthia G. Whitney · PubMed · 2010 · 421 citations
J. Pekka Nuorti, Cynthia G. Whitney · MMWR Morbidity and Mortality Weekly Report · 2010 · 373 citations
Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff et al. · Vaccine · 2013 · 165 citations · Full text